SATURDAY, November 10, 2018 (HealthDai Nevs) – Pharmaceutical Diabetes Farkiga can perform a double duty for patients, helping to avoid another killer, heart failure, show new research.
Type 2 diabetics who took Farkigo (dapagliphlozin) saw their hospitalization chances of reducing heart failure by 27 percent compared with those who took placebo, according to a study funded by Astra-Zeneca Drug Manufacturing Company.
"When it comes to helping our patients control and control blood glucose levels," how "it looks important [as] "How much," said the author of Dr. Stephen Viviott, a specialist in cardiovascular medicine at Brigham and Boston Women's Hospital.
"When choosing therapy, such trial results like this can help us decide which treatments are not only safe and effective to lower blood glucose but can also reduce the risk of heart and kidney complications," Viviott said in a statement to the hospital .
The findings were published on November 10 in New England Journal of Medicine, to coincide with their presentation at the annual meeting of the American Heart Association in Chicago.
The new study included more than 17,000 patients with type 2 diabetes, over 40 years of age. Nearly 7,000 had heart disease, and more than 10,000 had multiple risk factors for heart disease, said the Viviott Group.
Patients were randomly assigned to take or "dummy" a placebo tablet or 10 milligrams of Farki every day.
Taking a drug did not reduce the risk of heart attack, stroke and cardiovascular death, a research team found. However, patients taking this medicine saw a healthy drop in blood sugar, plus an additional bonus: a 27% reduction in the risk of hospitalization due to cardiac insufficiency.
Their risk of kidney failure and kidney deaths also dropped, the Boston team said.
Farkiga is a type of drug called the SGLT2 inhibitor. Two other recent studies of this type of drug show that they "diligently and consistently improve the heart and [kidney] outcomes in a wide population of diabetic patients, "Viviott noted.
A cardiologist who was not involved in the study said that the findings were a welcome news for people with diabetes.
"Unfortunately, more than 70 percent of deaths in patients with diabetes are of cardiovascular causes," Dr. Cindi Grines, who leads cardiology at North Shore University Hospital, Manhasset, N.I.
She noted that in the past there were concerns that some drugs for diabetes can damage the heart, but this new study shows that "there are now new drugs that have beneficial cardiovascular effects".
The Greens noted that fluid growth was a sign of heart failure. And since Farkiga "works by increasing the secretion of glucose in urine, it is not surprising that it reduces heart failure."
However, it was surprising that the medication was not a lower rate of heart attack or stroke.
The usual metformin for diabetes has However, it has been shown to reduce the risk for these cardiac events. So, "I would choose [Farxiga] to add metformin to patients with congestive heart failure, "added Grines.
According to Grines, patients with heart problems should avoid a single class of diabetes in particular.
"More research has shown that drug sulphonylureas – glipizide, glyburide and glimepiride – increased carcovascular mortality, heart attack, and congestive heart failure," she said, "so that sulfonylurea should be avoided in all patients with patients."
Another heart specialist has agreed that newer drugs such as Farkiga improve treatment for people with type 2 diabetes.
Farkiga is "a welcome addition to our armamentarium for reducing heart failure," said Dr. Marcin Kovalski, a cardiologist at the Staten Island University Hospital in New York. "It also raises that this group of drugs has not increased [negative] cardiovascular outcomes. "